Isolation of Small Extracellular Vesicles Derived from Mesenchymal Stem Cells from Large-Volume Samples with GMP Compliance for Clinical TrialsYixiao Zhou *1,2, Chunge Ren *1,2, Qiongfang Zhang 3, Pan Xie 3, Min Chen 1,2, Hongjia Zhang 1,2, Yanxia Wang 4, Qin Niu 4, Bianbaduojie 5, Yong Liu 1,2,6, Baishijiao Bian 1,2,5,6,7
1Southwest Hospital/Southwest Eye Hospital, Third Military Medical University (Army Medical University), 2Key Lab of Visual Damage and Regeneration & Restoration of Chongqing, 3Department of Nephrology, First Affiliated Hospital, Third Military Medical University (Army Medical University), 4Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University) and Key Laboratory of Tumor Immunopathology, 5Army 953 Hospital, Shigatse Branch of Xinqiao Hospital, Third Military Medical University (Army Medical University), 6Jinfeng Laboratory, 7Department of Trauma Medical Center, Daping Hospital, State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University
Small extracellular vesicles derived from mesenchymal stem cells (MSC-sEVs) have been underscored as a cell-free treatment modality with minimal adverse effects. This study provides a protocol combining hemodialysis with ultracentrifugation, significantly reducing the time spent on the entire process and ensuring compliance with good manufacturing practice (GMP) standards.
